Role of vasoactive intestinal peptide in inflammation and autoimmunity

Current Opinion in Investigational Drugs

Volumn 6, Issue 11, 2005, Pages 1116-1123

  Gonzalez Rey, Elena ^a   Delgado, Mario ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Autoimmunity; Inflammation; Neuroimmunology; Neuropeptides

Indexed keywords

CHEMOKINE; CYTOKINE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BRAIN INJURY; CELLULAR IMMUNITY; CROHN DISEASE; DENDRITIC CELL; DRUG EFFICACY; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; INHIBITION KINETICS; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MACROGLIA; MACROPHAGE; NONHUMAN; PARKINSON DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; T LYMPHOCYTE; TH2 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DRUG DESIGN; HOMEOSTASIS; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; LYMPHOID TISSUE; MACROPHAGES; MICROGLIA; NEURODEGENERATIVE DISEASES; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SHOCK, SEPTIC; T-LYMPHOCYTE SUBSETS; TH2 CELLS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 28244475755     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Eskandari F, Sternberg EM: Neural-immune interactions in health and disease. Ann NY Acad Sci (2002) 966:20-27.
2. Harbuz M: Neuroendocrine function and chronic inflammatory stress. Exp Physiol (2002) 87(5):519-525.
3. Webster JI, Tonelli L, Sternberg EM: Neuroendocrine regulation of immunity. Annu Rev Immunol (2002) 20:125-163.
4. Ganea D, Delgado M: Inhibitory neuropeptide receptors on macrophages. Microbes Infect (2001) 3(2):141-147.
5. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D: Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun (1999) 67(12):6603-6610.
6. Figen JW, Kobold AC, de Boer P, Jones CR, van der Werf TS, Tervaert JW, Zijlstra JG, Tylleken JE: Leukocyte activation and cytokine production during experimental human endotoxemia. Eur J Int Med (2000) 11(2):89-95.
7. Stallmach A, Strober W, MacDonald TT, Lochs H, Zeitz M: Induction and modulation of gastrointestinal inflammation. Immunol Today (1998) 19(10):438-441.
8. Martin R, Ruddle NH, Reingold S, Hafler DA: T helper cell differentiation in multiple sclerosis and autoimmunity. Immunol Today (1998) 19(11):495-498.
9. Geissler K: Current status of clinical development of interleukin-10. Curr Opin Hematol (1996) 3(3):203-208.
10. Cain BS, Meldrum DR, Harken AH, McIntyre RC: The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J Am Coll Surg (1998) 186(3):337-350.
11. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M: Immunology of VIP: A review and therapeutical perspectives. Curr Pharm Des (2001) 7(2):89-111.
12. Pozo D, Delgado M: The many faces of VIP in neuroimmunology: A cytokine rather a neuropeptide? FASEB J (2004) 18(12):1325-1334.
13. Delgado M, Pozo D, Ganea D: The significance of the vasoactive intestinal peptide in immunomodulation. Pharmacol Rev (2004) 56(2):249-290.
14. Pozo D, Delgado M, Martinez M, Guerrero JM, Leceta J, Gomariz RP, Calvo JR: Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today (2000) 21(1):7-11.
15. Said SI, Rosenberg RN: Vasoactive intestinal polypeptide: Abundant immunoreactivity in neural cell lines and normal nervous tissue. Science (1976) 192(4242):907-908.
16. Bellinger DL, Lorton D, Horn L, Brouxhon S, Felten SY, Felten DL: Vasoactive intestinal polypeptide (VIP) innervation of rat spleen, thymus, and lymph nodes. Peptides (1997) 18(8):1139-1149.
17. Gomariz RP, Lorenzo MJ, Cacicedo L, Vicente A, Zapata AG: Demonstration of immunoreactive vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus. Brain Behav Immun (1990) 4(2):151-161.
18. Gomariz RP, Leceta J, Garrido E, Garrido T, Delgado M: Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. Regul Pept (1994) 50(2):177-184.
19. Delgado M, Ganea D: Cutting Edge: Is vasoactive intestinal peptide a type 2 cytokine? J Immunol (2001) 166(5):2907-2912.
20. Delgado M, Leceta J, Gomariz RP, Ganea D: Vasoactive Intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol (1999) 163(7):3629-3635.
21. Delgado M, Leceta J, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J (2002) 16(13):1844-1846.
22. 2 receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA (2001) 98(24):13854-13859.
23. Voice JK, Dorsam G, Lee H, Kong Y, Goetzl EJ: Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J (2001) 15(13):2489-2496.
24. Harmar A, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna J, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA et al: International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev (1998) 50(2):265-270.
25. Usdin TB, Bonner TI, Mezey E: Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology (1994) 135(6):2662-2680.
26. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D: VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells. J Neuroimmunol (1999) 96(2):167-181.
27. Delgado M, Pozo D, Martínez C, Leceta J, Calvo JR, Ganea D, Gomariz RP: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF production by macrophages: in vitro and in vivo studies. J Immunol (1999) 162(4):2358-2367.
28. Delgado M, Muñoz-Elías EJ, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: In vitro and in vivo studies. J Immunol (1999) 162(3):1707-1716.
29. Delgado M, Muñoz-Elías EJ, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and IFN regulatory factor 1 activation. J Immunol (1999) 162(8):4685-4696.
30. Delgado M, Gomariz RP, Martinez C, Abad C, Leceta J: Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: Role in lethal endotoxic shock. Eur J Immunol (2000) 30(11):3236-3246.
31. Delgado M, Jonakait GM, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia (2002) 39(2):148-161.
32. Delgado M, Leceta J, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J Leukocyte Biol (2003) 73(1):155-164.
33. Martínez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, Gomariz RP: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukocyte Biol (1998) 63(5):591-601.
34. Delgado M, Ganea D: Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem Biophys Res Commun (2003) 301(4):825-832.
35. Delgado M, Ganea D: Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol (2001) 167(2):966-975.
36. Delgado M, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-κB-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem (2001) 276(1):369-380.
37. Delgado M: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-κB interaction in activated microglia. Biochem Biophys Res Commun (2002) 297(5):1181-1185.
38. Delgado M: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. Biochem Biophys Res Commun (2002) 293(2):771-776.
39. Delgado M: Inhibition of interferon (IFN) γ-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: Inhibitory effect on CD40, IFN-incluced protein-10, and inducible nitric-oxide synthase expression. J Biol Chem (2003) 278(30):27620-27629.
40. Delgado M, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor κB and Ets activation. J Biol Chem (1999) 274(45):31930-31940.
41. Delgado M, Ganea D: Inhibition of IFN-γ-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol (2000) 165(6):3051-3057.
42. Delgado M, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. J Neuroimmunol (2000) 110(1-2):97-105.
43. Delgado M: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia. Biochem Biophys Res Commun (2002) 293(2):771-776.
44. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today (1994) 15(7):321-331.
45. Delgado M, Sun W, Leceta J, Ganea D: VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. J Immunol (1999) 163(8):4213-4223.
46. Delgado M, Reduta A, Sharma V, Ganea D: VIP/PACAP oppositely affect immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity of CD4+ T cells. J Leukocyte Biol (2004) 75(6):1122-1130.
47. O'Garra A: Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity (1998) 8(3):275-283.
48. Kim WK, Ganea D, Jonakait GM: Inhibition of microglial CD40 expression by pituitary adenylate cyclase activating polypeptide is mediated by interleukin 10. J Neuroimmunol (2002) 126(1-2):16-24.
49. Voice JK, Grinninger A, Kong Y, Bangale Y, Paul S, Goetzl EJ: Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol (2003) 170(1):308-314.
50. Ranger AM, Das MP, Kuchroo VK, Glimcher LM: B7-2 (CD86) is essential for the development of II-4 producing T cells. Int Immunol (1996) 8(10):1549-1560.
51. Andrew DP, Chang M, McNinch J, Wathen ST, Rihanek M, Tseng J, Spielberg JP, Elias CG 3rd: STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol (1998) 161(9):5027-5038.
52. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F: Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 187(1):129-134.
53. Delgado M, Gonzalez-Rey E, Ganea D: VIP/PACAP preferentially attract Th2 versus Th1 cells by differentially regulating the production of chemokines by dendritic cells. FASEB J (2004) 18(12):1453-1455.
54. Delgado M, Leceta J, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J (2002) 16(13):1844-1846.
55. Wang HY, Jiang XM, Ganea D: The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. J Neuroimmunol (2000) 104(1):68-78.
56. Netea MG, van der Meer JW, van Deuren M, Kullberg BJ: Proinflammatory cytokines and sepsis syndrome: Not enough, or too much of a good thing? Trends Immunol (2003) 24(5):254-258.
57. Delgado M, Pozo D, Martinez C, Leceta J, Calvo J, Ganea D, Gomariz RP: Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: In vitro and in vivo studies. J Immunol (1999) 162(4):2358-2367.
58. Tuncel N, Tore F, Sahinturk V, Ak D, Tuncel M: Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: A potential therapeutic strategy in controlling septic shock. Peptides (2000) 21(1):81-89.
59. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med (2001) 7(5):563-568.
60. Williams RO: Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum (2002) 46(1):271-273.
61. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 14:397-440.
62. Delgado M, Abad C, Martinez C, Juarranz G, Arranz A, Gomariz RP, Leceta J: Vasoactive intestinal peptide in the immune system: Potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med (2002) 80(1):16-24.
63. Strober W, Fuss IJ, Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol (2002) 20:495-549.
64. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology (2003) 124(4):961-971.
65. Nguyen MD, Julien JP, Rivest S: Innate immunity: The missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci (2002) 3(3):216-227.
66. Delgado M, Ganea D: Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: Potential therapeutic role in brain trauma. FASEB J (2003) 17(13):1922-1924.
67. Delgado M, Ganea D: Neuroprotective act of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J (2003) 17(8):944-946.
68. Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, Cohen A, Kuchroo V, Cohen IR, Weiner H, Schwartz M: Protective autoimmunity is a physiological response to CNS trauma. J Neurosci (2001) 21(11):3740-3748.